-
Our study shows that DAB2IP harbored frameshift mutations and intratumoral heterogeneity as well as expression loss in gastric and colorectal cancers
-
The results indicated significant down-regulation of DAB2IP transcript variant 1 in prostatic cancerous tissues compared to paired normal tissues
-
The role of miR-367 in the pathogenesis of osteosarcoma via DAB2IP expression is reported.
-
mutp53 augments insulin-induced AKT1 activation by binding and inhibiting the tumor suppressor DAB2IP (DAB2-interacting protein) in the cytoplasm
-
variants DAB2IP-rs7025486[A] and SORT1-rs599839[G] are associated with abdominal aortic aneurysm expansion.
-
Low expression of DAB2IP is associated with nasopharyngeal carcinoma.
-
These findings suggest that DAB2IP is a direct target of miRNA-556-3p, and endogenous miRNA-556-3p expression shows inverse correlation with simultaneous DAB2IP expression in bladder cancer (BC)tissues and cells. miRNA-556-3p functions as a tumor promoter in tumorigenesis and metastasis of BC by targeting DAB2IP
-
Low DAB2IP expression is associated with neoplasms.
-
Results identified PRRT2 and DAB2IP to be frequently mutated in all different cancer cell line types. Further analysis showed that both genes were also frequently mutated in colorectal and endometrial cancer patient samples.
-
Data suggest that DAB2IP CpG1 methylation is a practical and repeatable biomarker for renal cell carcinoma (ccRCC), which can provide prognostic value that complements the current staging system.
-
PROX1 overexpression in DAB2IP-deficient prostate cancer cells could enhance the accumulation of HIF1alpha protein by inhibiting ubiquitin pathway and then consequently induce an epithelial-mesenchymal transition response.
-
Study shows that up to 62% of luminal B cancers have lost expression of at least one of the DAB2IP and RASAL2 genes. However, the tumors that have lost both genes frequently present as advanced disease and are more likely to recur. Importantly, the report provide evidence that DAB2IP and RASAL2 can individually function as tumor suppressors in breast cancer.
-
The low expression of DAB2IP in bladder carcinoma cells was related to drug resistance.
-
Down-regulation of DAB2IP correlated negatively with hnRNPK and MMP2 expressions in CRC tissues. In conclusion, our study elucidates a novel mechanism of the DAB2IP/hnRNPK/MMP2 axis in the regulation of CRC invasion and metastasis, which may be a potential therapeutic target.
-
DAB2IP appears to be a new prognostic/predictive marker for metastatic renal cell cancer (mRCC) patients, and its function provides a new insight into the molecular mechanisms of drug resistance to mTOR inhibitors, which also can be used to develop new strategies to overcome drug-resistant mRCC.
-
Along with the reduction of ovarian cancer-2/disabled homolog 2 (DOC-2/DAB2) interactive protein (DAB2IP) expression, EGR-1 gene was upregulated in FI-treated cells. On the other hand, downregulation of EGR-1 gene expression sensitized radioresistant cells to IR accompanied by DAB2IP overexpression and STAT3 inactivation. In addition, NF-kappaB inhibitor, BAY11-7082 enhanced resistant cells' radiosensitivity and chemos...
-
Our findings demonstrate a novel function of DAB2IP in the maintenance of KT-MT structure and SAC regulation during mitosis which is essential for chromosomal stability.
-
DAB2IP may be involved in forming acquired radioresistance in PC3 cells. DAB2IP-deficient cells are resistant to low and high-LET radiation using different mechanisms. DAB2IP-deficient cells are resistant to both gamma-rays and alpha-particles.
-
our data provided evidence to verify that miR-92b was able to directly target DAB2IP, a well-known tumor suppressor, and inhibit epithelialmesenchymal transition of bladder cancer cells
-
DAB2IP protein levels are higher in bladder cancer than in upper tract urothelial carcinoma and in superficial bladder cancer